Product Description
Cardiotrophin-1 (CT-1) is a member of the IL-6 family of cytokines which was originally discovered as a factor which can induce hypertrophy of cardiac myocytes both in vitro and in vivo. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2517776/)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Digna Biotech S.L.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Kidney Transplant
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CT1-HEPT-01, 2010-022929-15 | P1 |
Unknown status |
Healthy Volunteers |
2013-08-01 |
|
| 2011-004223-12 | P2 |
Terminated |
Kidney Transplant |
2013-07-26 |